MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines

Gene

Volumn 340, Issue 1, 2004, Pages 53-59

  Duan, Zhenfeng ^a   Brakora, Katherine A ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemotherapy resistance; Gene expression; mammalian gene collection; MDR; MDR1; MDR1 and mitochondrial taxol resistance associated gene; MGC; Mitochondrial protein; MM TRAG; multidrug resistance; multidrug resistance gene 1; open reading frame; ORF; RT PCR

Indexed keywords

AMINO ACID; COMPLEMENTARY DNA; DOXORUBICIN; GREEN FLUORESCENT PROTEIN; MITOCHONDRIAL PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CHROMOSOME 7Q; COMPARATIVE STUDY; DISEASE ASSOCIATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN GENOME; MITOCHONDRIAL TAXOL RESISTANCE ASSOCIATED GENE; MITOCHONDRION; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SEQUENCE ANALYSIS; SOUTHERN BLOTTING; STRUCTURAL HOMOLOGY;

BLOTTING, NORTHERN; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 7; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MICROSCOPY, PHASE-CONTRAST; MITOCHONDRIAL PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PHENOTYPE; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

MAMMALIA;

EID: 5444270424     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2004.06.013     Document Type: Article

References (19)

1. Abbaszadegan M.R., Foley N.E., Gleason-Guzman M.C., Dalton W.S. Resistance to the chemosensitizer verapamil in a multi-drug-resistant (MDR) human multiple myeloma cell line. Int. J. Cancer. 66:1996;506-514
2. Brockstein B., Haraf D.J., Stenson K., Fasanmade A., Stupp R., Glisson B., Lippman S.M., Ratain M.J., Sulzen L., Klepsch A., Weichselbaum R.R., Vokes E.E. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J. Clin. Oncol. 16:1998;735-744
3. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:1987;936-942
4. Duan Z., Feller A.J., Penson R.T., Chabner B.A., Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin. Cancer Res. 5:1999;3445-3453
5. Duan Z., Feller A.J., Toh H.C., Makastorsis T., Seiden M.V. TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. Gene. 229:1999;75-81
6. Duan Z., Duan Y., Lamendola D.E., Yusuf R.Z., Naeem R., Penson R.T., Seiden M.V. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin- resistant human cancer cell lines. Clin. Cancer Res. 9:2003;2778-2785
7. Duan Z., Lamendola D.E., Duan Y., Yusuf R., Seiden M.V. Description of paclitaxel resistance associated genes in ovarian and breast cancer cell lines. 2004;. Submitted to Cancer Res.
8. Dumontet C., Duran G.E., Steger K.A., Beketic-Oreskovic L., Sikic B.I. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res. 56:1996;1091-1097
9. Ferreira C.G., Tolis C., Giaccone G. p53 and chemosensitivity. Ann. Oncol. 10:1999;1011-1021
10. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., Poruchynsky M.S. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem. 272:1997;17118-17125
11. Lamendola D.E., Duan Z., Yusuf R.Z., Seiden M.V. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res. 63:2003;2200-2205
12. Loe D.W., Deeley R.G., Cole S.P. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer. 32A:1996;945-957
13. McGuire W.P., Blessing J.A., Moore D., Lentz S.S., Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J. Clin. Oncol. 14:1996;792-795
14. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
15. Scheffer G.L., Wijngaard P.L., Flens M.J., Izquierdo M.A., Slovak M.L., Pinedo H.M., Meijer C.J., Clevers H.C., Scheper R.J. The drug resistance-related protein LRP is the human major vault protein. Nat. Med. 1:1995;578-582
16. Schinkel A.H., Roelofs E.M., Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res. 51:1991;2628-2635
17. Volm M. Multidrug resistance and its reversal. Anticancer Res. 18:1998;2905-2917
18. Watts G.S., Futscher B.W., Isett R., Gleason-Guzman M., Kunkel M.W., Salmon S.E. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J. Pharmacol. Exp. Ther. 299:2001;434-441
19. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets. 3:2003;1-19